Inhibition of tumor cell surface ATP synthesis by pigment epithelium-derived factor: Implications for antitumor activity

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 219-227

  Deshpande, Monika ^a   Notari, Luigi ^b   Subramanian, Preeti ^a   Notario, Vicente ^c   Becerra, S Patricia ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

ATP; ATP synthase; ATP synthesis; Cell viability; PEDF; Tumor cell

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKER; F1 ADENOSINE TRIPHOSPHATE SYNTHASE BETA SUBUNIT; PICEATANNOL; POLYPEPTIDE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RECOMBINANT PIGMENT EPITHELIUM DERIVED FACTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL DEATH; CELL MEMBRANE; CELL SURFACE; CELL TYPE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMPEDANCE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SYNTHESIS; TUMOR CELL;

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITORS; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; EYE PROTEINS; HUMANS; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; NERVE GROWTH FACTORS; PEPTIDE FRAGMENTS; PROTEIN SUBUNITS; SERPINS; STILBENES;

EID: 84862875249     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1431     Document Type: Article

References (45)

1. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V and Di Virgilio F: Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PloS One 3: e2599, 2008.
2. + transporting ATP synthase on the surface of tumor cell lines. J Exp Med 180: 273-281, 1994.
3. Chi SL and Pizzo SV: Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase. Cancer Res 66: 875-882, 2006. (Pubitemid 43165953)
4. Yamamoto K, Shimizu N, Obi S, et al: Involvement of cell surface ATP synthase in flow-induced ATP release by vascular endothelial cells. Am J Physiol Heart Circ Physiol 293: H1646-H1653, 2007. (Pubitemid 47367211)
5. Kim BW, Choo HJ, Lee JW, Kim JH and Ko YG: Extracellular ATP is generated by ATP synthase complex in adipocyte lipid rafts. Exp Mol Med 36: 476-485, 2004.
6. Burrell HE, Wlodarski B, Foster BJ, et al: Human keratinocytes release ATP and utilize three mechanisms for nucleotide interconversion at the cell surface. J Biol Chem 280: 29667-29676, 2005. (Pubitemid 41177043)
7. Martinez LO, Jacquet S, Esteve JP, et al: Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421: 75-79, 2003. (Pubitemid 36077087)
8. Champagne E, Martinez LO, Collet X and Barbaras R: Ecto-F1Fo ATP synthase/F1 ATPase: metabolic and immunological functions. Curr Opin Lipidol 17: 279-284, 2006. (Pubitemid 43786062)
9. Mowery YM and Pizzo SV: Targeting cell surface F1F0 ATP synthase in cancer therapy. Cancer Biol Ther 7: 1836-1838, 2008.
10. Vantourout P, Radojkovic C, Lichtenstein L, Pons V, Champagne E and Martinez LO: Ecto-F1-ATPase: a moonlighting protein complex and an unexpected apoA-I receptor. World J Gastroenterol 16: 5925-5935, 2010.
11. +-ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. Mol Cancer Res 1: 931-939, 2003.
12. Moser TL, Kenan DJ, Ashley TA, et al: Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 98: 6656-6661, 2001. (Pubitemid 32538272)
13. Lu ZJ, Song QF, Jiang SS, et al: Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen. BMC Cancer 9: 16, 2009.
14. Notari L, Arakaki N, Mueller D, Meier S, Amaral J and Becerra SP: Pigment epithelium-derived factor binds to cell-surface F(1)-ATP synthase. FEBS J 277: 2192-2205, 2010.
15. Becerra SP: Focus on molecules: Pigment epithelium-derived factor (PEDF). Exp Eye Res 82: 739-740, 2006.
16. Bouck N: PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 8: 330-334, 2002.
17. Filleur S, Nelius T, de Riese W and Kennedy RC: Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem 106: 769-775, 2009.
18. Yabe T, Sanagi T and Yamada H: The neuroprotective role of PEDF: implication for the therapy of neurological disorders. Curr Mol Med 10: 259-266, 2010.
19. Crawford SE, Stellmach V, Ranalli M, et al: Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 114: 4421-4428, 2001. (Pubitemid 34082862)
20. Broadhead ML, Dass CR and Choong PF: In vitro and in vivo biological activity of PEDF against a range of tumors. Expert Opin Ther Targets 13: 1429-1438, 2009.
21. Ek ET, Dass CR and Choong PF: PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 12: 497-502, 2006. (Pubitemid 44468197)
22. Hoshina D, Abe R, Yamagishi SI and Shimizu H: The role of PEDF in tumor growth and metastasis. Curr Mol Med 10: 292-295, 2010.
23. Doll JA, Stellmach VM, Bouck NP, et al: Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 9: 774-780, 2003. (Pubitemid 36749229)
24. Becerra SP, Sagasti A, Spinella P and Notario V: Pigment epithelium-derived factor behaves like a noninhibitory serpin. Neurotrophic activity does not require the serpin reactive loop. J Biol Chem 270: 25992-25999, 1995.
25. Notari L, Baladron V, Aroca-Aguilar JD, et al: Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem 281: 38022-38037, 2006. (Pubitemid 46042106)
26. Bernard A, Gao-Li J, Franco CA, Bouceba T, Huet A and Li Z: Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium-derived factor. J Biol Chem 284: 10480-10490, 2009.
27. Park K, Lee K, Zhang B, et al: Identification of a novel inhibitor of the canonical Wnt pathway. Mol Cell Biol 31: 3038-3051, 2011.
28. Alberdi E, Hyde CC and Becerra SP: Pigment epithelium-derived factor (PEDF) binds to glycosaminoglycans: analysis of the binding site. Biochemistry 37: 10643-10652, 1998. (Pubitemid 28357865)
29. Becerra SP, Perez-Mediavilla LA, Weldon JE, et al: Pigment epithelium-derived factor binds to hyaluronan. Mapping of a hyaluronan binding site. J Biol Chem 283: 33310-33320, 2008.
30. Meyer C, Notari L and Becerra SP: Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J Biol Chem 277: 45400-45407, 2002. (Pubitemid 36159148)
31. Amaral J and Becerra SP: Effects of human recombinant PEDF protein and PEDF-derived peptide 34-mer on choroidal neovascularization. Invest Ophthalmol Vis Sci 51: 1318-1326, 2010.
32. Filleur S, Volz K, Nelius T, et al: Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 65: 5144-5152, 2005. (Pubitemid 40827323)
33. Mirochnik Y, Aurora A, Schulze-Hoepfner FT, et al: Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res 15: 1655-1663, 2009.
34. Alberdi E, Aymerich MS and Becerra SP: Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons. Evidence for a PEDF receptor. J Biol Chem 274: 31605-31612, 1999.
35. Bilak MM, Becerra SP, Vincent AM, Moss BH, Aymerich MS and Kuncl RW: Identification of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons. J Neurosci 22: 9378-9386, 2002. (Pubitemid 35356181)
36. Stratikos E, Alberdi E, Gettins PG and Becerra SP: Recombinant human pigment epithelium-derived factor (PEDF): characterization of PEDF overexpressed and secreted by eukaryotic cells. Protein Sci 5: 2575-2582, 1996. (Pubitemid 26424870)
37. Shao R and Guo X: Human microvascular endothelial cells immortalized with human telomerase catalytic protein: a model for the study of in vitro angiogenesis. Biochem Biophys Res Commun 321: 788-794, 2004. (Pubitemid 39044379)
38. Rasband WS: Image Processing with ImageJ. Biophotonics Int 11: 36-42, 1997.
39. Quillen EE, Haslam GC, Samra HS, et al: Ectoadenylate kinase and plasma membrane ATP synthase activities of human vascular endothelial cells. J Cell Biochem 281: 20728-20737, 2006. (Pubitemid 44115414)
40. Chowdhury SA, Kishino K, Satoh R, et al: Tumor-specificity and apoptosis-inducing activity of stilbenes and flavonoids. Anticancer Res 25: 2055-2063, 2005. (Pubitemid 40904604)
41. Wolter F, Clausnitzer A, Akoglu B and Stein J: Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J Nutr 132: 298-302, 2002. (Pubitemid 34135611)
42. Huang TC, Chang HY, Hsu CH, Kuo WH, Chang KJ and Juan HF: Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J Proteome Res 7: 1433-1444, 2008.
43. van Raaij MJ, Abrahams JP, Leslie AG and Walker JE: The structure of bovine F1-ATPase complexed with the antibiotic inhibitor aurovertin B. Proc Natl Acad Sci USA 93: 6913-6917, 1996. (Pubitemid 26243474)
44. Hong S and Pedersen PL: ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas. Microbiol Mol Biol Rev 72: 590-641, 2008.
45. Zhang X, Gao F, Yu LL, et al: Dual functions of a monoclonal antibody against cell surface F1F0 ATP synthase on both HUVEC and tumor cells. Acta Pharmacol Sin 29: 942-950, 2008.